McGuire Annie 4

What Happened Annie McGuire, SVP and General Counsel of Veracyte, sold a total of 6,658 shares in two open‑market transactions on March 4, 2026. She sold 4,994 shares at a weighted average price of $35.29 for proceeds of $176,256 and 1,664 shares at a weighted average price of $36.34 for proceeds of $60,469 — about $236,725 combined. These were sales (S), not purchases.

Key Details

• Transaction dates: March 4, 2026 (both sales).
• Prices and ranges: first block weighted avg $35.29 (individual sale prices ranged $35.00–$35.89, per footnote); second block weighted avg $36.34 (prices ranged $36.17–$36.48, per footnote).
• Total shares sold: 6,658; total proceeds: ≈ $236,725.
• Plan: Transactions were made under a Rule 10b5‑1 trading plan adopted by the reporting person on August 29, 2025 (footnote F1).
• Detailed per‑share price counts are available to the SEC/issuer/shareholders on request (footnotes F2/F3).
• Filing timeliness: Report filed March 6, 2026 for transactions on March 4 — appears to be timely (within the two business‑day Form 4 filing window).
• Shares owned after transaction: not disclosed in the materials provided.

Context

• These were open‑market sales executed under a pre‑arranged 10b5‑1 plan, which generally means the trades followed a pre‑set schedule and may reflect routine portfolio or tax planning rather than a contemporaneous judgment about the company. Sales are common and don’t necessarily signal management’s view of Veracyte’s prospects; purchases are typically viewed as a stronger bullish indicator.